Go to Contents
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec
(JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec
Partnership
IR/PR
Notice & News
Financials
IR Inquiries
SUBSIDIARY
About SillaJen Biotherapeutics
Contact Us
Sillajen Sitemap
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec (JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec Partnership
IR/PR
Notice & News
Financials
IR Inquiries
SUBSIDIARY
About SillaJen Biotherapeutics
Contact Us
ENG
|
KOR
ENG
ENG
KOR
Targeting, Attacking, and Eradicating Cancers®
TOP
IR/PR
ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
IR/PR
SUBSIDIARY
Notice & News
Notice & News
Stock Information
Financials
IR Inquiries
Notice & News
게시판
Enrollment of the First European Patient in Multinational Phase 3 Trial
2017-04-24
Targeting, Attacking, and Eradicating Cancers®
